Women’s health · Menopause · Medication safety
After an Estella ad that says you can skip hormones, can you stop menopausal hormone therapy?
No. “Skip hormones” names a product category; it is not an order to stop menopausal hormone therapy.
Stopping on your own lets vasomotor symptoms rebound, and if you still have a uterus it also disturbs progestogen protection of the endometrium.
Decide with the clinician who prescribed the treatment.
Red flag symptoms that need care now, not a supplement adjustment
If any of the following apply, contact your clinician or go to an emergency department first,
without waiting for a product to take effect and without waiting for a routine appointment.
- Any vaginal bleeding after menopause, however light, including occasional brown spotting.
- A new breast or underarm lump, skin dimpling or unusual redness, or one-sided nipple discharge or bleeding.
- One-sided leg swelling with calf tenderness and warm red skin, which suggests deep vein thrombosis.
- Sudden breathlessness, chest pain on inspiration, or coughing blood, which may indicate pulmonary embolism.
- Facial droop, one-sided weakness, slurred speech, or sudden visual loss, or the worst headache of your life.
- Chest pain or pressure radiating to the jaw, arm, or back with sweating and palpitations.
- Yellow eyes or skin, severe right upper abdominal pain, or unusually dark urine.
- If you take warfarin: easy bruising, nosebleeds that will not stop, heavy gum bleeding,
black tarry stools, or blood in the urine.
Nothing on the list above can, and none of those findings is improved by adding or changing a supplement.
An advertisement is not a prescription, so it is not a reason to stop your treatment
Direct answer: do not stop menopausal hormone therapy (MHT) because of an advertising phrase.
“Skip hormones” on a marketplace listing communicates that the item belongs to the dietary supplement
category rather than the hormone medicine category. That is a fact about product classification,
not advice about your treatment. The person who can say whether you should continue, reduce,
change route, or stop is the clinician who knows your history and your test results.
Stopping MHT abruptly has two predictable consequences.
First, vasomotor symptoms such as hot flashes and night sweats typically return within weeks,
and many people experience them as more intense than before starting,
because the body had adapted to a steady estradiol level.
Second, and only in people who still have a uterus, estrogen has to be paired with a progestogen
such as medroxyprogesterone to protect against endometrial hyperplasia.
Changing the regimen incompletely therefore disturbs that balance directly.
so they carry no assessed dose, no assessed route of administration,
and no paired progestogen the way MHT does. Substituting one for the other is not an equivalent switch;
it is stopping treatment and starting a supplement.
Four groups who must not make this swap on their own
Direct answer: if you belong to any of the groups below, switching from MHT to a dietary supplement
by yourself is not merely ineffective; it risks a missed diagnosis or a preventable harm.
Each group has its own clinical reason.
1. Unexplained vaginal bleeding after menopause
Postmenopausal bleeding requires evaluation in every case, because it is the most common presenting symptom
of endometrial cancer. Standard assessment includes a pelvic examination,
transvaginal ultrasound to measure endometrial thickness,
and endometrial sampling where indicated. In this situation a supplement contributes no diagnostic
information at all; it only lets time pass with the cause still unknown.
2. A history of hormone-sensitive cancer
People treated for breast or endometrial cancer have a treatment and surveillance plan set by specialists.
Everything they swallow should pass in front of the treating clinician,
because some ingredients can interfere with the medicines already in use.
An advertising phrase claiming no cancer risk carries no status as oncology clearance.
3. A history of venous thromboembolism or stroke
This group usually already carries a contraindication or a strong caution against systemic hormone therapy,
so their care plan is individualised: non-hormonal options,
low-dose vaginal estrogen for local symptoms, or avoiding hormones altogether.
Adding a multi-botanical product on your own can interfere with the anticoagulant
or antiplatelet medicines that plan depends on.
4. Anyone taking warfarin or another anticoagulant
The
NCCIH
states that dong quai may interact with warfarin, and several other botanicals popular in menopause formulas
have reported effects on blood clotting. The outcome to watch for is an unstable INR
that leads either to easy bleeding or to clot formation.
If your clinician approves combined use, expect more frequent INR checks at the start.
This page explains general principles for all readers. It does not diagnose or comment on
any individual person who has shared their story on a forum or on social media.
Individual decisions require examination findings and history that only exist in the consultation room.
“No cancer risk” is marketing language, not an oncology assessment
Direct answer: a listing that says no cancer risk or free of estrogen-like activity
is not the same thing as long-term follow-up data showing no effect on the recurrence
of hormone-sensitive cancer.
The two differ in both the type of data and how it is obtained.
A cancer safety question is answered by following groups of patients for years
and comparing rates of new disease or recurrence between those exposed and not exposed to what is studied.
Laboratory data showing that an extract does not bind the estrogen receptor
is the beginning of a hypothesis, not an answer about clinical outcomes in people.
There is a second point that is usually overlooked. If a formula genuinely has no estrogen-like activity,
then it has no mechanism to replace what MHT does to reduce vasomotor symptoms.
The same sentence therefore cannot serve as both a safety guarantee and an effectiveness guarantee.
This is explained in detail in
the third article in this cluster.
Want to talk to a clinician but unsure which information to bring?
Review your severity level and receive personalized guidance from our Advisory team.
Take the free menopause symptom assessment
Women’s health category:
Menopause and women’s health hub
Decision table: your situation compared with what the ad suggests
Direct answer: in every situation that involves a contraindication or a red flag symptom,
the clinical answer is to evaluate first, not to swap first.
The table uses drug classes and generic names only, so it can be taken straight into a consultation.
| Your situation | What the ad suggests | What clinical guidance advises | Medical reason |
|---|---|---|---|
| On MHT, symptoms well controlled, no side effects | Stop the medicine and switch to a dietary supplement | Continue therapy and review benefit and risk with your clinician at scheduled visits | NAMS 2022 describes a favourable benefit-risk balance for people under 60 or within 10 years of menopause onset without contraindications |
| Vaginal bleeding after menopause | Take a hormone-balancing supplement and wait to see if it settles | See a gynaecologist for pelvic examination, transvaginal ultrasound, and endometrial sampling where indicated | It is the most common presenting symptom of endometrial cancer, where outcome depends on the stage at diagnosis |
| History of hormone-sensitive breast or endometrial cancer | Trust the no cancer risk phrase and start on your own | Show the label and full ingredient list to your treating oncology clinician first | Marketplace phrasing is not an oncology assessment, and some ingredients can interfere with current medicines |
| History of venous thromboembolism or stroke | Use a natural formula instead, assuming it carries no risk | Review the plan with your clinician; non-hormonal options or low-dose vaginal estrogen for local symptoms may be appropriate | This group carries strong cautions against systemic hormone therapy, and natural does not guarantee no effect on clotting |
| Taking warfarin or another anticoagulant | Combine freely because it is a supplement rather than a medicine | Ask your clinician and pharmacist first; if combined, expect more frequent INR checks initially | The NCCIH states dong quai may interact with warfarin, destabilising INR toward bleeding or clotting |
| Main problem is vaginal dryness and painful intercourse | Take an oral supplement to restore whole-body moisture | Discuss low-dose vaginal estrogen together with lubricants and vaginal moisturisers | The genitourinary syndrome of menopause responds well to local therapy at a lower dose than systemic treatment |
| You prefer to avoid hormones entirely, for personal reasons | Use a dietary supplement as the main alternative to treatment | Discuss non-hormonal options with trial data: SSRIs and SNRIs such as paroxetine and venlafaxine, gabapentin, and the NK3 receptor antagonist fezolinetant | Choosing to avoid hormones does not mean there are no evidence-based options, and these are monitored systematically for side effects |
| You want to take a supplement alongside your current MHT | Take both immediately because one of them is only a supplement | Disclose the product name and full ingredient list to your clinician and pharmacist for an interaction check first | Many botanicals affect the hepatic enzymes that metabolise medicines, changing blood levels without warning symptoms |
Scientific mechanism: why stopping on your own causes symptoms to rebound
By
Asst. Prof. Dr. Norawit Raatpiboon
(ผศ.ดร.นรวิชญ์ ราษฎร์พิบูลย์):
vasomotor symptoms reflect a narrowing of the thermoneutral zone in the hypothalamus
when estradiol is low and fluctuating. Under MHT, a steady estradiol level widens that zone again,
which is why symptoms subside. Stopping abruptly removes the input that stabilised the system,
so thermoregulatory control returns rapidly to its hypersensitive state,
and patients perceive the symptoms as worse than before because they are comparing against a controlled period.
In people who still have a uterus there is a second mechanism to respect.
Estrogen stimulates endometrial proliferation, and a progestogen such as medroxyprogesterone
counterbalances that to reduce the risk of endometrial hyperplasia.
Adjusting the regimen yourself, by stopping one component and keeping the other,
or stopping them at different times, disturbs that balance.
That is the mechanistic reason why changes must go through a clinician.
Finally, a dietary supplement that itself declares it has no estrogen-like activity
cannot take over either of those two roles, because it does not act at the same site.
Using it as a replacement is therefore not a medication switch but a discontinuation of treatment,
combined with the introduction of a new variable that may interact with medicines you already take.
Frequently asked questions
An ad says you can skip hormones. Does that mean I can stop the hormone therapy my doctor prescribed?
No. Skip hormones is marketing language used to say that a product is not a hormone medicine.
It is not clinical advice to stop a prescription.
Stopping menopausal hormone therapy on your own usually brings vasomotor symptoms back quickly
and often more intensely than before, because the body had adapted to a steady estradiol level.
In people who still have a uterus and take estrogen together with a progestogen,
stopping only part of the regimen or stopping the components at different times
also disturbs endometrial protection.
The right move is to take the advertisement or the product you are curious about
to the gynaecologist who prescribed your therapy and decide together whether to continue,
reduce the dose, change the route, or stop.
Who must never swap from MHT to a dietary supplement on their own?
There are four main groups who should not make this decision alone.
The first is anyone with unexplained vaginal bleeding after menopause,
because the endometrium has to be evaluated first in every case.
The second is anyone with a history of hormone-sensitive cancer such as breast or endometrial cancer,
whose oncology team needs to review everything they swallow.
The third is anyone with a history of venous thromboembolism or stroke,
whose care plan is already individualised around that risk.
The fourth is anyone taking warfarin or another anticoagulant,
because many botanical ingredients can affect blood clotting.
I have vaginal bleeding after menopause. Can I take a supplement and wait to see if it settles?
No. Vaginal bleeding after menopause, even light spotting or a brown discharge,
requires evaluation in every case, because it is the most common presenting symptom of endometrial cancer.
Standard assessment includes a pelvic examination,
transvaginal ultrasound to measure endometrial thickness,
and endometrial sampling where the clinician judges it indicated.
Delaying that assessment to see whether a dietary supplement helps costs diagnostic time
in a condition where the outcome depends clearly on the stage at diagnosis.
An ad says the product carries no cancer risk. Is that a safety clearance for cancer?
No. A no cancer risk phrase on a marketplace listing is not an oncology assessment
and has no status equivalent to clearance for use in cancer patients.
Stating that a formula is free of estrogen-like activity describes a property of the formula;
it is not long-term follow-up data showing no effect on the recurrence of hormone-sensitive cancer.
Anyone with that history should show the label and the full ingredient list
to their treating clinician before starting,
because some ingredients can interfere with the medicines they are already taking.
I take warfarin. Can I take a menopause supplement alongside it?
Always ask your clinician and pharmacist first.
The NCCIH states that dong quai may interact with warfarin,
and several botanicals commonly added to menopause formulas have reported effects on blood clotting.
The important risk is an unstable INR leading either to easy bleeding or to clot formation,
and users often do not notice until symptoms appear.
If your clinician approves combined use, expect more frequent INR checks at the start,
and report immediately any easy bruising, nosebleeds that will not stop,
or blood in the urine or stool.
If I genuinely want to come off MHT, how do I do it safely?
Start with an appointment with the clinician who prescribes your therapy to review three things:
the original goal of treatment, your current symptoms,
and how your risk profile has changed with age and other conditions.
Then plan together whether to taper the dose gradually,
change the route of administration such as moving from oral therapy to transdermal estradiol,
switch to low-dose vaginal estrogen if your main problem is genitourinary,
or move to a non-hormonal option.
A plan with follow-up catches returning symptoms early
and avoids the abrupt stop that usually causes a symptom rebound.
I read a forum thread where someone described my exact symptoms. Can that replace seeing a clinician?
No, and this article does not diagnose any individual forum poster either.
Shared experiences are useful for arriving at better questions before a consultation,
but they lack the information a decision requires: pelvic examination findings, endometrial thickness,
cancer and clotting history, a full medication list, and time since menopause.
Two people with similar symptoms can need entirely different management.
The productive way to use a thread is to write down the questions it raises and ask your own clinician.
Read next in this cluster
The first layer explains the product category and the one-month timeframe.
The third layer explains how to check the research an advertisement cites.
Academic citations (E-E-A-T)
-
NAMS 2022 hormone therapy position statement (PMID 35797481)
— MHT is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause,
with a favourable benefit-risk balance for people under 60 or within 10 years of menopause onset
and without contraindications. -
USPSTF 2022 recommendation statement (PMID 36318127)
— D recommendation against systemic hormone therapy for the primary prevention of chronic conditions,
a different layer of question from treating menopausal symptoms
(full recommendation page). -
NCCIH — Menopausal Symptoms: In Depth
— notes there is little research on dong quai for menopause and that it may interact with warfarin. -
National Institute on Aging — What Is Menopause?
— defines menopause as the point twelve months after the final menstrual period. -
ACOG — Hormone Therapy FAQ
— patient-facing information on shared decision-making and monitoring of hormone therapy. -
dr9ohm.com — Perimenopause symptoms guide (40+)
— background on the hormonal mechanisms of the transition.
Author and content reviewer:
Asst. Prof. Dr. Norawit Raatpiboon
(ผศ.ดร.นรวิชญ์ ราษฎร์พิบูลย์)
Medical disclaimer
This article is educational information about the safety of changing menopausal hormone treatment.
It is not a diagnosis, not a prescription, and not an opinion about any individual case,
including anyone who has shared their experience on a forum or on social media.
Naming a dietary supplement here describes its regulatory category only.
Starting, adjusting, tapering, or stopping menopausal hormone therapy
must happen under the assessment of your own clinician.
Seek care immediately for vaginal bleeding after menopause, a new breast lump,
one-sided leg swelling, sudden breathlessness, chest pain, or sudden neurological symptoms.
If you have thoughts of self-harm, contact your local emergency number or crisis line right away;
in Thailand the mental health hotline 1323 is available 24 hours a day.